Drug
SC10914
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Other(3)
Detailed Status
unknown3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
unknown3100%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_2
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
NCT04556539
unknownphase_2
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
NCT04556292
unknownphase_1
A Study of SC10914 in Patients With Advanced Solid Tumors
NCT02940132
Clinical Trials (3)
Showing 3 of 3 trials
NCT04556539Phase 2
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
NCT04556292Phase 2
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients
NCT02940132Phase 1
A Study of SC10914 in Patients With Advanced Solid Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3